Procter & Gamble Hygiene and Health Care (500459) Transition period summary

Executive summary

• Audited financial results for the nine months ended March 31, 2025, were approved, with the period shortened due to a change in the financial year-end from June 30 to March 31.

• A final dividend of Rs. 65 per equity share was recommended, subject to shareholder approval.

• The statutory auditors issued an unmodified opinion on the financial statements.

Financial highlights

• Revenue from operations for the nine months ended March 31, 2025, was Rs. 336,812 lakhs, up from Rs. 326,415 lakhs in the comparable prior period.

• Net profit for the nine months ended March 31, 2025, was Rs. 63,659 lakhs, compared to Rs. 59,396 lakhs in the previous comparable period.

• Earnings per share (basic and diluted) for the nine months ended March 31, 2025, were Rs. 196.11, up from Rs. 182.98 year-over-year.

• Total comprehensive income for the nine months ended March 31, 2025, was Rs. 62,953 lakhs.

Outlook and guidance

• The Board recommended a final dividend of Rs. 65 per equity share, to be paid between August 27, 2025, and September 23, 2025, upon approval at the AGM.